Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women

Journal of Bone and Mineral Research

Volumn 17, Issue SUPPL. 2, 2002, Pages

  Insogna, Karl ^a   Mitnick, Maryann ^a   Pascarella, Jennifer ^a   Nakchbandi, Inaam ^a   Grey, Andrew ^a   Masiukiewicz, Urszula ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Hyperparathyroidism; Interleukin 6; Interleukin 6 soluble receptor

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PARATHYROID HORMONE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYTOKINE; ESTROGEN; PEPTIDE;

BONE DISEASE; BONE TURNOVER; CLIMACTERIUM; CONFERENCE PAPER; CYTOKINE RELEASE; ESTROGEN METABOLISM; HORMONAL REGULATION; HUMAN; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; RISK ASSESSMENT; ADULT; ANIMAL; ARTICLE; BLOOD; BONE; DISEASE MODEL; DRUG EFFECT; FEMALE; FOLLOW UP; HYPERPARATHYROIDISM; MENOPAUSE; METABOLISM; MIDDLE AGED; MOUSE; OSTEOLYSIS; PHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION AND FORECASTING; REFERENCE VALUE; RETROSPECTIVE STUDY; URINE;

ADULT; ANIMALS; BONE AND BONES; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; CYTOKINES; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM; INTERLEUKIN-6; MENOPAUSE; MICE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; RECEPTORS, INTERLEUKIN-6; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 0036840456     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Silverberg S, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian J 1995 Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 80:723-728.
2. Silverberg S, Shane E, Jacobs T, Siris E, Bilezikan J 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255.
3. Grey A, Stapleton J, Evans M, Reid I 1996 Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 44:697-702.
4. Guo C-Y, Thomas W, Al-dehaimi A, Assiri A, Eastell R 1996 Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487-3491.
5. Koshla S, Melton J III, Wermers R, Crowson C, O'Fallon W, Riggs L 1999 Primary hyperparathyroidism and the risk of fracture: A population-based study. J Bone Miner Res 14:1700-1701.
6. Vestergaard P, Mollerup CL, Gedso Frokjaer V, Christiansen P, Blichert-Toft M, Mosekilde L 2000 Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598-602.
7. Cosman F, Shen V, Fang X, Seibel M, Ratcliffe A, Lindsay R 1993 Estrogen protection against bone resorbing effects of parathyroid hormone infusion: Assessment by use of biochemical markers. Ann Intern Med 118:337-343.
8. Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P, Mosekilde L 1997 Primary hyperparathyroidism: Biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93-99.
9. Grey A, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K 1996 Circulating levels of interleukin-6 are elevated in primary hyperparathyroidism and correlate with markers of bone resorption. J Clin Endocrinol Metab 10:3450-3454.
10. May L, Viguet H, Kenney J, Ida N, Allison A, Sehgal P 1992 High levels of "complexed" interleukin-6 in human blood. J Biol Chem 267:19698-19704.
11. Horowitz M, Brown M, Insogna K, Coleman D, Centrella M, Phillips J, Weir E 1990 PTHrP and PTH induce the secretion of IL-6 by a clonal osteosarcoma cell line. In: Powanda MD, Oppenheim JJ, Kluger MJ, Dinnarello CA (eds.) Molecular and Cellular Biology of Cytokines. Wiley-Liss, Inc., New York, NY, USA, pp. 471-476.
12. Tamura T, Ugadawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, Kishimoto T, Suda T 1993 Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90:11924-11928.
13. Grey A, Mitnick M, Masiukiewicz U, Sun B-H, Rudikoff S, Jilka R, Manolagas S, Insogna K 1999 A role for interleukin-6 in parathyroid hormone induced bone resorption in vivo. Endocrinology 140:4683-4690.
14. Nakchbandi I, Mitnick M, Gundberg C, Lang R, Kinder B, Insogna K 2000 Circulating levels of IL-6 soluble receptor predict bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab (In press.)
15. Masiukiewicz U, Mitnick M, Gulanski B, Insogna K 2002 Evidence that the interleukin-6/interleukin-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to parathyroid hormone in estrogen-deficient women. J Clin Endocriol Metab 87:2892-2898.
16. Nakchbandi I, Mitnick M, Masiukiewicz U, Sun B, Insogna K 2001 IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 142:3850-3856.
17. Nakchbandi I, Masiukiewicz U, Mitnick M, Grey A, Insogna K 2001 Cytokines in primary hyperparathyroidism. In: Belizikan J, Levine M, Marcus R (eds.) The Parathyroids. Academic Press, San Diego, CA, USA, pp. 411-421.
18. Mastorakos G, Chrousos G, Weber J 1993 Recombinant interleukin-6 activates the hypothalamic-pituitary adrenal axis in humans. J Clin Endocrinol Metab 77:12690-1694.
19. Mitnick M, Grey A, Masiukiewicz U, Bartkicwicz M, RiosVelez L, Friedman S, Xu L, Horowitz M, Insogna K 2001 Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol 280:E405-E412.
20. Stein B, Yang M 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κ B and C/EBPβ. Mol Cell Biol 15:4971-4979.
21. Ray P, Ghosh S, Zhang D, Ray A 1997 Repression of interleukin-6 gene expression by 17β-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kB by the estrogen receptor. FEBS Lett 409:79-85.
22. Jilka R, Hangoc G, Girasole G, Passeri G, Williams D, Abrams J, Boyce B, Broxmeyer H, Manolagas S 1992 Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91.
23. Poli V, Balena R, Fattori E, Markatos A, Yamamoto A, Tanaka H, Ciliberto G, Rodan G, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196.
24. Straub R, Hense H, Andus T, Scholerich J, Riegger A, Schunkert H 2000 Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study. J Clin Endocrinol Metab 85:1340-1344.
25. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Sibel M, Ziegler R, Pfeilschifter J 2001 Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 86:2023-2042.
26. Khosla S, Peterson J, Egan K, Jones J, Riggs B 1994 Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 79:707-711.
27. Kudo O, Sabokbar A, Itonaga I, Fujikawa Y, Torisu T, Athanasou N 2001 Human osteoclast formation and bone resorption by a mechanism independent of RANK/RANKL: Role of IL-6 and IL-11. J Bone Miner Res 16:S1;S381
28. Zhang J, Devalaraja R, Dai J, Baragi V, Keller E 2000 Osteoprotegerin (OPG) and anti-interleukin-6 (IL-6) antibody inhibit osteoclastogenesis induced by prostate cancer cells in vitro. J Bone Miner Res 15:S1;S209.
29. Mitnick M, Sun B, McCarthy S, Insogna K 2002 The IL-6/IL-6 soluble receptor cytokine system plays a role in mediating PTH-induced soluble RANKL release. J Bone Miner Res (In press.)